Dermapharm Holding SE (HAM:DMP) Days Sales Outstanding : 32.96 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Days Sales Outstanding?

Dermapharm Holding SE's average Accounts Receivable for the three months ended in Mar. 2024 was €108 Mil. Dermapharm Holding SE's Revenue for the three months ended in Mar. 2024 was €299 Mil. Hence, Dermapharm Holding SE's Days Sales Outstanding for the three months ended in Mar. 2024 was 32.96.

The historical rank and industry rank for Dermapharm Holding SE's Days Sales Outstanding or its related term are showing as below:

HAM:DMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.95 Med: 21.34 Max: 36.31
Current: 36.31

During the past 11 years, Dermapharm Holding SE's highest Days Sales Outstanding was 36.31. The lowest was 17.95. And the median was 21.34.

HAM:DMP's Days Sales Outstanding is ranked better than
83.25% of 997 companies
in the Drug Manufacturers industry
Industry Median: 71.44 vs HAM:DMP: 36.31

Dermapharm Holding SE's Days Sales Outstanding increased from Mar. 2023 (28.91) to Mar. 2024 (32.96).

Dermapharm Holding SE Days Sales Outstanding Historical Data

The historical data trend for Dermapharm Holding SE's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Days Sales Outstanding Chart

Dermapharm Holding SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

21.61

24.00

24.78

30.14

30.16

Dermapharm Holding SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															28.91	37.36	37.42	36.39	32.96

Competitive Comparison of Dermapharm Holding SE's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermapharm Holding SE's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Days Sales Outstanding falls into.

Dermapharm Holding SE Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Dermapharm Holding SE's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (96.715	+	90.935)	/	2 )	/	1135.351	*	365
=	93.825					/	1135.351	*	365
=	30.16

Dermapharm Holding SE's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (90.935	+	124.814)	/	2 )	/	298.691	*	365 / 4
=	107.8745					/	298.691	*	365 / 4
=	32.96

Dermapharm Holding SE (HAM:DMP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Dermapharm Holding SE Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermapharm Holding SE (HAM:DMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (HAM:DMP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

0A5J:UK DMP:Germany

Address

Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031

Website

https://www.dermapharm.de

Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs and natural remedies. Its portfolio of products includes cosmetics, nutritional supplements and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals and cosmetics products. Parallel import brands business operates under the AxiCorp brand.

Dermapharm Holding SE (HAM:DMP) Headlines

No Headlines